Search Results
May 15, 2026, 03:43 ET Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
control arm, with a composite complete remission (CRc) rate of 56.7% versus 53.3%. Among patients achieving CRc, the measurable residual disease (MRD) negativity rate was higher in the ligufalimab arm (46.7% versus 36.7%).Median duration of CRc was substantially longer in the ligufalimab arm
More news about: Akeso, Inc.
May 14, 2026, 16:02 ET Inhibrx Reports First Quarter 2026 Financial Results
study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC);Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ozekibart
More news about: Inhibrx Biosciences, Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
plasma DKK1 biomarker assay and results based on Part B of the DeFianCe study of sirexatamab plus bevacizumab and chemotherapy in colorectal cancer ("CRC") patients at the American Association for Cancer Research (AACR) 2026:At AACR 2026 in April, the Company presented a new plasma
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
plasma DKK1 biomarker assay and results based on Part B of the DeFianCe study of sirexatamab plus bevacizumab and chemotherapy in colorectal cancer ("CRC") patients at the American Association for Cancer Research (AACR) 2026:At AACR 2026 in April, the Company presented a new plasma
More news about: Cypherpunk Technologies Inc.
May 11, 2026, 09:00 ET Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
G12DKRAS G12D is one of the most prevalent oncogenic drivers in solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). For decades, this mutation was considered "undruggable". RNK08954 is designed to bind directly to the Switch
More news about: Ranok Therapeutics
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovationHOPEWELL, N.J., May. 11, 2026 /PRNewswire/ -- Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and
More news about: ProBio Inc.
May 10, 2026, 20:00 ET Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
MSS/pMMR Colorectal CancerColorectal cancer (CRC) is one of the most common malignancies worldwide, with MSS/pMMR being the predominant subtype, accounting for approximately 95% of advanced CRC cases. For patients with advanced MSS/pMMR CRC who have failed standard therapies, there remains a
More news about: Innovent Biologics
May 06, 2026, 02:34 ET Steel Demand Is Rising Across Sectors with Market Size Exceeding USD 1.7 Trillion, Market Decipher
India Cold-Rolled Coil (CRC) Steel — Precision Drives PremiumsThe India HRC and CRC market is forecast to deliver a CAGR of 8.2% in revenue and 8.4% in volume through 2033. Domestic steel demand hit 132.74 MT in FY23 and is projected to reach 163.85 MT by FY25. CRC, widely used in automotive
More news about: Market Decipher
May 04, 2026, 09:00 ET John Hancock Adds to U.S. Sales and Distribution Leadership with Key Appointments, Expands Executive Benefits Business
the Board of Transamerica Capital, LLC. Earlier in his career, Carney spent nearly two decades at Truist Insurance Holdings, holding C‑suite roles at CRC Group and Crump Life Insurance Services, helping build and scale one of the nation's largest life insurance distribution platforms.Ortale is stepping
More news about: John Hancock
May 04, 2026, 08:09 ET Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
clinical studies. Tegavivint is currently being evaluated in a Phase 1/2 clinical trial in advanced HCC and in investigator-sponsored studies in metastatic CRC, EGFR-mutated non-small cell lung cancer, and relapsed or refractory pediatric osteosarcoma.About Iterion TherapeuticsIterion
More news about: Iterion Therapeutics
Apr 29, 2026, 23:13 ET D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
strategies to enhance the durability of response in CRC. For late-line PDAC, monotherapy (n=20) achieved an ORR of 65.0%, mDoR of 10.8 months, and mPFS of 13.5 months.Favorable Safety ProfileElisrasib was well-tolerated across NSCLC, CRC, and PDAC populations. Grade 3 or higher treatment-related
More news about: D3 Bio
Apr 21, 2026, 16:05 ET Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC).
More news about: Inhibrx Biosciences, Inc.
Apr 21, 2026, 15:30 ET Greenberg Traurig's Fred E. Karlinsky Named to News Service of Florida's '50 Over 50' List
from 2022-2025 — six of the seven sitting justices have been appointed during his tenure. He previously served on the Constitution Revision Commission (CRC) and serves annually on U.S. Sen. Rick Scott's Military Academy Selection Committee.Karlinsky serves as President of the Florida Supreme
More news about: Greenberg Traurig, LLP
Apr 20, 2026, 17:03 ET Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC).
More news about: Inhibrx Biosciences, Inc.
Apr 20, 2026, 08:00 ET Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
are known to harbor abnormalities of the Wnt/β-catenin signaling pathway, including colorectal cancer (CRC). ST316 is currently being evaluated in the Phase 2 dose expansion portion of the study in CRC patients in combination with relevant standards of care and in multiple lines of treatment. The U.S.
More news about: Sapience Therapeutics, Inc.
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
activity across a broad spectrum of tumor cell lines, including non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), colorectal cancer (CRC), squamous cell carcinoma (SCCHN), pancreatic cancer (PANC), and breast cancer (BC).5. Significant Bystander Killing EffectThe bystander
More news about: CStone Pharmaceuticals
Apr 17, 2026, 15:00 ET Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
expansion (BCE) of IMT-009 (IMT) in advanced cancer and Phase 1b (Ph1b) combination with fruquintinib (F) in microsatellite stable colorectal cancer (MSS CRC)," highlights Phase 1/2a results supporting continued evaluation of IMT-009 as both a monotherapy and combination treatment for patients with solid tumors
More news about: Immunitas Therapeutics, Inc.
Apr 15, 2026, 08:30 ET Fundamental Underwriters Names Diamond Club Winners
The Diamond Club Award winners are:CRC GroupUSI DallasRT Specialty/Crouse"Our Diamond Club Award winners are all repeat winners, who continue to demonstrate
More news about: Fundamental Underwriters
Apr 15, 2026, 08:00 ET CRC's Chief Scientific Officer, Gary Kay, Ph.D., to Speak at 2026 Lifesavers Conference on Roadway Safety
regulatory outcomes. CRC also brings experience supporting complex neuropsychiatric programs, including 10 psychedelic clinical trials involving specialized regulatory, scientific, and operational expertise. With 20 years of exclusive focus on central nervous system clinical research, CRC supports programs
More news about: Cognitive Research Corporation
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
Association for Cancer Research (AACR) Annual Meeting. The data demonstrate ABT-301's superior performance in enhancing immunotherapy for colorectal cancer (CRC) and reveal a novel mechanism for overcoming chemotherapy resistance in pancreatic cancer. AnBogen will present these breakthroughs during the
More news about: Anbogen Therapeutics
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
Association for Cancer Research (AACR) Annual Meeting. The data demonstrate ABT-301's superior performance in enhancing immunotherapy for colorectal cancer (CRC) and reveal a novel mechanism for overcoming chemotherapy resistance in pancreatic cancer. AnBogen will present these breakthroughs during the
More news about: Anbogen Therapeutics
Apr 11, 2026, 01:45 ET Building an Ecosystem of Thalassemia Care - Manipal Hospital Yelahanka Leads the Way, A Step Towards Stronger, More Compassionate Futures
DEPWD, Department of Empowerment of Differently Abled and Senior Citizen, Govt. Of Karnataka, Sri Kanagasabhapathi, Rehabilitation officer, CRC (central govt), and Dr Meera, Consultant – Haematology, Victoria Hospital, all contributing meaningfully to the cause with their valuable insights.This
More news about: Manipal Hospitals
Apr 09, 2026, 12:33 ET Euclid Transactional Announces 21 Senior-Level Promotions Globally
CRC Group. Learn more at www.euclidtransactional.com.About CRC Group CRC
More news about: Euclid Transactional, LLC
Apr 06, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
advance another potential first-in-class agent into the clinic that targets large solid tumor indications of high unmet need, including breast, prostate, CRC, and lung cancer. We believe the novel chromatin remodeling mechanism of the KAT6/7 dual inhibitor IDE574, has the potential for monotherapy efficacy
More news about: IDEAYA Biosciences, Inc.
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
observed in the monotherapy trial targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, colorectal cancer (CRC), neuroendocrine neoplasm (NEN) and hepatocellular carcinoma (HCC).In October 2025, the Company published positive Phase II clinical data in combination
More news about: Harbour BioMed